Publications by authors named "M A Gamaleldin"
Article Synopsis
- Pharmacogenomics (PGx) links genetic differences to drug responses, aiming to enhance treatment outcomes and minimize side effects, but it's underutilized in developing countries.
- Surveys conducted in Egypt and Lebanon revealed limited availability of PGx testing in healthcare facilities, with Egypt having some testing and Lebanon offering almost none.
- There is significant interest among pharmacists (over 34%) and physicians (almost 25%) in learning about PGx, with a consensus on the necessity for educational programs to improve PGx implementation in the Middle East.
Article Synopsis
- DiDBiT is a new proteomic technique that enhances the detection of newly synthesized proteins by 20 times compared to traditional methods.
- The new method, DiDBiT-TMT, allows for the quantification of these proteins across multiple conditions and replicates in a single experiment.
- Using DiDBiT-TMT on brain slices, researchers found distinct differences in newly synthesized proteins following different treatments, suggesting unique molecular processes at play in response to chemical long-term potentiation and norepinephrine.
Background: β-thalassemia major is microcytic hypochromic anemia disorder inherited from parents, resulting from a mutation in the β-globin locus. As a result, a quantitative defective hemoglobin synthesis and relative excess in α-globin is occurred. As such, frequent blood transfusion is required, that leads to iron overload.
View Article and Find Full Text PDFPurpose: Locoregional recurrence after resection of colon cancer is increased when primary tumor margin is positive (<1 mm). Data is limited regarding the risk of locoregional recurrence with close margin (<1 mm) of histologic factors, such as intravascular tumor, intranodal tumor, tumor deposits, or extranodal extension. We hypothesized that close margin of these factors doesn't affect locoregional recurrence.
View Article and Find Full Text PDFIntroduction: Limited data on atrial fibrillation (AF) are available from the Middle East and North Africa region (MENA). The aim of the FLOW-AF registry was to evaluate the characteristics, treatment patterns, and clinical and economic outcomes of patients with newly diagnosed non-valvular atrial fibrillation (NVAF) in MENA.
Methods: This multi-center, prospective, observational study (the FLOW-AF registry) enrolled patients newly diagnosed with NVAF across Egypt, Lebanon, Kingdom of Saudi Arabia, and United Arab Emirates.